Compare RGTI & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGTI | PTCT |
|---|---|---|
| Founded | 2013 | 1998 |
| Country | United States | United States |
| Employees | N/A | 991 |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 5.4B |
| IPO Year | 2021 | 2006 |
| Metric | RGTI | PTCT |
|---|---|---|
| Price | $16.80 | $63.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 17 |
| Target Price | $30.78 | ★ $80.65 |
| AVG Volume (30 Days) | ★ 14.6M | 918.2K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 35.78 | ★ 264.48 |
| EPS | N/A | ★ 0.90 |
| Revenue | $13,102,000.00 | ★ $264,734,000.00 |
| Revenue This Year | $225.06 | N/A |
| Revenue Next Year | $99.56 | $17.70 |
| P/E Ratio | ★ N/A | $69.20 |
| Revenue Growth | ★ 59.86 | 36.19 |
| 52 Week Low | $12.53 | $58.90 |
| 52 Week High | $58.15 | $90.87 |
| Indicator | RGTI | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 56.06 | 35.34 |
| Support Level | $15.05 | $63.29 |
| Resistance Level | $19.15 | $68.93 |
| Average True Range (ATR) | 0.89 | 1.97 |
| MACD | 0.20 | -0.31 |
| Stochastic Oscillator | 71.96 | 24.18 |
Rigetti Computing Inc builds quantum computers and the superconducting quantum processors that power them. The Company sells 9-qubit to 108-qubit quantum computing systems under the Novera and Cepheus trade names. Through the Rigetti Quantum Cloud Services (QCS) platform, the Company's machines can be integrated into any public, private or hybrid cloud. The Company also operates in Fremont, California; London, United Kingdom; Adelaide, Australia; British Columbia, Canada and Mumbai, India. The Company's revenue is derived from operations in the United States and the United Kingdom.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.